Inhibition of extracellular signal-regulated kinase1/2 mitogen-activated protein kinase (MAPK/ERK1/2) activity by MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma (MM) cell apoptosis and inhibits osteoclasts within the bone marrow (BM) microenvironment

被引：0
|
作者：
Tai, Y. T.
Hideshima, T.
Song, W.
Li, X. F.
Rumizen, M.
Burger, P.
Morrison, A.
Podar, K.
Schlossman, R.
Richardson, P.
Munshi, N. C.
Ghobrial, I.
Smith, P.
Anderson, K. C.
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[2] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：147 / 147
页数：1
相关论文
共 42 条
  • [1] Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM.
    Tai, Yu-Tzu
    Li, Xian-Feng
    Breitkreutz, Iris
    Song, Weihua
    Burger, Peter
    Rumizen, Matthew
    Hideshima, Teru
    Podar, Klaus
    Ghobrial, Irene
    Schlossman, Robert
    Richardson, Paul
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 987A - 987A
  • [2] In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase
    Chung, Eun Joo
    Brown, Aaron P.
    Asano, Hiroaki
    Mandler, Mariana
    Burgan, William E.
    Carter, Donna
    Camphausen, Kevin
    Citrin, Deborah
    CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3050 - 3057
  • [3] The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts
    Shannon, Aoife M.
    Telfer, Brian A.
    Smith, Paul D.
    Babur, Muhammed
    Logie, Armelle
    Wilkinson, Robert W.
    Debray, Camille
    Stratford, Ian J.
    Williams, Kaye J.
    Wedge, Stephen R.
    CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6619 - 6629
  • [4] The Mitogen-activated Protein Kinase (MAPK)/Extracellular Signal-regulated Kinase (ERK) 1/2 Kinase Inhibitor, AZD6244 (ARRY-142886) Enhances Radiosensitivity by Interfering with Radiation-induced TGF-alpha Signaling
    Chung, E.
    Urick, M.
    Kurshan, N.
    Shield, W.
    Riley, H.
    Citrin, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S564 - S564
  • [5] Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
    Yeh, Tammie C.
    Marsh, Vivienne
    Bernat, Bryan A.
    Ballard, Josh
    Colwell, Heidi
    Evans, Ron J.
    Parry, Janet
    Smith, Darin
    Brandhuber, Barbara J.
    Gross, Stefan
    Marlow, Allison
    Hurley, Brian
    Lyssikatos, Joe
    Lee, Patrice A.
    Winkler, James D.
    Koch, Kevin
    Wallace, Eli
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1576 - 1583
  • [6] The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
    Haass, Nikolas K.
    Sproesser, Katrin
    Nguyen, Thiennga K.
    Contractor, Rooha
    Medina, C. Angelica
    Nathanson, Katherine L.
    Herlyn, Meenhard
    Smalley, Keiran S. M.
    CLINICAL CANCER RESEARCH, 2008, 14 (01) : 230 - 239
  • [7] AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
    Davies, Barry R.
    Logie, Armelle
    McKay, Jennifer S.
    Martin, Paul
    Steele, Samantha
    Jenkins, Richard
    Cockerill, Mark
    Cartlidge, Sue
    Smith, Paul D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (08) : 2209 - 2219
  • [8] AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor blocks the ERK1/2 signaling pathway, inhibits osteoclast differentiation and activation in multiple myeloma: Clinical implications.
    Breitkreutz, Iris
    Vallet, Sonia
    Raab, Marc S.
    Li, Xianfeng
    Raje, Noopur
    Hideshima, Teru
    Chauhan, Dharminder
    Munshi, Nikhil
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    BLOOD, 2006, 108 (11) : 989A - 989A
  • [9] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Adjei, Alex A.
    Cohen, Roger B.
    Franklin, Wilbur
    Morris, Clive
    Wilson, David
    Molina, Julian R.
    Hanson, Lorelei J.
    Gore, Lia
    Chow, Laura
    Leong, Stephen
    Maloney, Lara
    Gordon, Gilad
    Simmons, Heidi
    Marlow, Allison
    Litwiler, Kevin
    Brown, Suzy
    Poch, Gregory
    Kane, Katie
    Haney, Jerry
    Eckhardt, S. Gail
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2139 - 2146
  • [10] Hyperexpression of extracellular signal-regulated protein kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK) in cultured Caucasian melanocytes
    Zhang, KH
    Nip, J
    Pocalyko, D
    Barratt, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (03) : 744 - 744
12345